Program
JMKX003142
A development code. Also written as “JMKX003142 tablets”, “JMKX003142 Injection” and “JMKX003142 will be administered orally”.
Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Edema · Heart Failure, led by Jemincare.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jemincare | 119 open or running | phase 3since Sep 7, 2026 | Oct 6, 2023 | Feb 28, 2027phase 2 · NCT06800651 |
Also a collaborator on its studies: zhejiang-hangyu-pharmaceutical-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 6, 2023First study: phase 1 study in Safety and TolerabilityFirst studyNCT06079541 · 106 planned · China
- Mar 18, 2024Phase 1 study in Healthy AdultNCT06344533 · 78 planned · China
- Oct 23, 2024Phase 1 study in Polycystic Kidney, Autosomal DominantNCT06658964 · 48 planned
- Oct 31, 2024Phase 2 study in Edema SecondaryNCT06670534 · 133 enrolled · China
- Jan 20, 2025Phase 2 study in Polycystic Kidney, Autosomal DominantNCT06800651 · 135 planned · China
- Apr 22, 2025Phase 2 study in Edema, CardiacNCT06949020 · 160 enrolled · China
- Mar 2, 20262 phase 1 studies in Polycystic Kidney, Autosomal DominantNCT07463053, NCT07470177
- Apr 27, 2026Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07565441 · 112 planned
- Sep 7, 2026Phase 3 study in EdemaPhase 3 reachedNCT07841093 · 240 planned · China
- Oct 26, 2026Phase 1 study in Polycystic Kidney, Autosomal DominantNCT07909070 · 32 planned
Ahead
- Nov 15, 2026Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07565441
- Feb 28, 2027Primary completion: phase 2 study in Polycystic Kidney, Autosomal DominantNCT06800651
- May 30, 2027Primary completion: phase 1 study in Polycystic Kidney, Autosomal DominantNCT07909070
- Apr 30, 2028Primary completion: phase 3 study in EdemaNCT07841093
TargetBeta
“JMKX003142 is an arginine vasopressin(AVP)-V2R antagonist which shows a remarkable diuretic effect in healthy volunteers(phase 1 study) and renal edema patients(phase 2 study).In this phase 3 study ,we will observe the safety 、efficacy about JMKX003142 tablet in renal edema who have an inadequate…”study text, by rule · the study
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07909070Polycystic Kidney, Autosomal Dominant | 1 | Not yet recruiting | May 30, 2027 | 32 |
| NCT07841093Edema · China | 3 | Not yet recruiting | Apr 30, 2028 | 240 |
| NCT07565441Polycystic Kidney, Autosomal Dominant | 1 | Not yet recruiting | Nov 15, 2026 | 112 |
| NCT07470177Polycystic Kidney, Autosomal Dominant | 1 | Not yet recruiting | May 14, 2026 | 24 |
| NCT07463053Polycystic Kidney, Autosomal Dominant | 1 | Not yet recruiting | May 7, 2026 | 8 |
| NCT06949020Edema, Cardiac · China | 2 | Completed | Mar 14, 2026 | 160 |
| NCT06800651Polycystic Kidney, Autosomal Dominant · China | 2 | Recruiting | Feb 28, 2027 | 135 |
| NCT06670534Edema Secondary · China | 2 | Completed | Apr 27, 2026 | 133 |
| NCT06658964Polycystic Kidney, Autosomal Dominant | 1 | Not yet recruiting | Dec 10, 2024 | 48 |
| NCT06344533Healthy Adult · China | 1 | Not yet recruiting | Jan 31, 2025 | 78 |
| NCT06079541Safety and Tolerability · China | 1 | Recruiting | Jul 31, 2024 | 106 |
How it is read
Names in the registry
- “JMKX003142 tablets”, 8 entries
- “JMKX003142 Injection”, 4 entries
- “JMKX003142 will be administered orally”, 4 entries
- “JMKX003142”, 1 entry
- “JMKX003142 Tablets”, 1 entry
Codes read as this program: JMKX003142.
Conditions, from the studies’ own filings
- Polycystic Kidney, Autosomal Dominant, 6 studies
- Edema, 2 studies
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.